Real-world study on the efficacy and safety of Ritlecitinib in Chinese patients with severe alopecia areata: A single-center, prospective, observational study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500095989

Enrollment

Unknown

Registered

2025-01-15

Start date

2025-02-01

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alopecia areata

Interventions

ritlecitinib:None

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: 1 Males or females, >= 12 years of age 2 Patients with severe AA (meet the criteria of severe based on alopecia areata scale [AAS]); 3 Patients who wish to be treated with Ritlecitinib 4 Patients who sign the informed consent.

Exclusion criteria

Exclusion criteria: 1)Allergy to Ritlecitinib or any component of the study drug; 2)Patients who are currently pregnant, breastfeeding, or planning a pregnancy during the study observation period; 3)History of substance abuse, suicide attempts, or mental illness; 4)diffuse type or Alopecia areata incognita; 5)Other circumstances that investigators don't consider appropriate to include.

Design outcomes

Primary

Measure	Time frame
Severity of hair loss;Pattern of administration of rituxinib;	—

Secondary

Measure	Time frame
quality of life;	—

Countries

China

Contacts

Public ContactWei Shi

Xiangya Hospital, Central South University

shiwei@csu.edu.cn+86 139 7317 9150

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026